[S02DA03, antipyrine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Carboplatin.]
[J01GA01, streptomycin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Streptomycin is combined with Carboplatin.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Carboplatin.]
[L04AA27, fingolimod, Carboplatin may increase the immunosuppressive activities of Fingolimod.]
[A02BX02, sucralfate, Carboplatin may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Carboplatin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Carboplatin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Carboplatin.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Carboplatin.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Carboplatin.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Mercaptopurine.]
[N05CD07, temazepam, Carboplatin may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Carboplatin.]
[R03CC03, terbutaline, Carboplatin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Carboplatin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Carboplatin may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Tetracaine.]
[S03AA02, tetracycline, Carboplatin may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftaroline fosamil.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Carboplatin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Eribulin.]
[R06AD03, thiethylperazine, Carboplatin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Carboplatin is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Carboplatin.]
[G04BE06, moxisylyte, Carboplatin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Carboplatin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Carboplatin.]
[S01ED01, timolol, Carboplatin may decrease the excretion rate of Timolol which could result in a higher serum level.]
[P01AB02, tinidazole, Carboplatin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Tobramycin is combined with Carboplatin.]
[A10BB05, tolazamide, Carboplatin may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Carboplatin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Carboplatin.]
[N02AX02, tramadol, Carboplatin may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Carboplatin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Carboplatin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Carboplatin.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Carboplatin.]
[N05CD05, triazolam, Carboplatin may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Carboplatin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Carboplatin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Carboplatin.]
[A03AA05, trimebutine, Carboplatin may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01EA01, trimethoprim, Carboplatin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Carboplatin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Belimumab.]
[L01FX04, ipilimumab, Carboplatin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Carboplatin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Carboplatin.]
[S01AA28, vancomycin, Carboplatin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Carboplatin is combined with Belatacept.]
[N03AX21, ezogabine, Carboplatin may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Carboplatin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Carboplatin.]
[C08DA01, verapamil, Carboplatin may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, Carboplatin may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Carboplatin.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Carboplatin.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Carboplatin.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carboplatin.]
[B01AA03, warfarin, Carboplatin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Carboplatin.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Carboplatin.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Tiludronic acid.]
[B06AC02, icatibant, Carboplatin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.]
[A02BC04, rabeprazole, Carboplatin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Ibandronate.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Carboplatin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin.]
[N02BA01, aspirin, The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Carboplatin.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ruxolitinib.]
[G04BD07, tolterodine, Carboplatin may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Carboplatin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carboplatin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Carboplatin.]
[M01CB03, auranofin, Carboplatin may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Carboplatin is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Carboplatin.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Carboplatin.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Carboplatin.]
[J01DF01, aztreonam, Carboplatin may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Carboplatin.]
[M03BX01, baclofen, Carboplatin may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Carboplatin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin.]
[A08AA11, lorcaserin, Carboplatin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Carboplatin may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Carfilzomib.]
[L02BB04, enzalutamide, Carboplatin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Carboplatin.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Carboplatin is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Aldosterone.]
[D02BA02, octinoxate, Carboplatin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Bendamustine.]
[N04BD02, rasagiline, Carboplatin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L04AA29, tofacitinib, Carboplatin may increase the immunosuppressive activities of Tofacitinib.]
[V09IX04, fluorodeoxyglucose F18, Carboplatin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[V08CA11, gadofosveset, Carboplatin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Carboplatin.]
[A16AX08, teduglutide, Carboplatin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Carboplatin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Carboplatin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Carboplatin is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Benzocaine.]
[L03AA12, ancestim, Carboplatin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Carboplatin.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Carboplatin is combined with Everolimus.]
[N04AC01, benztropine, Carboplatin may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Benzydamine.]
[L01EE01, trametinib, Carboplatin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Carboplatin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Carboplatin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Carboplatin may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, Carboplatin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Carboplatin may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ibrutinib.]
[N06AX26, vortioxetine, Carboplatin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Carboplatin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[J05AP08, sofosbuvir, Carboplatin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Carboplatin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Carboplatin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Carboplatin is combined with Apremilast.]
[L02BG02, formestane, Carboplatin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Carboplatin.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Carboplatin.]
[V03AB34, fomepizole, Carboplatin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Carboplatin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Carboplatin.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Carboplatin is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Carboplatin is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Carboplatin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Carboplatin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Dihydrostreptomycin is combined with Carboplatin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pirfenidone.]
[S03AA06, gentamicin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Gentamicin is combined with Carboplatin.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Carboplatin.]
[B01AF03, edoxaban, Carboplatin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Carboplatin is combined with Panobinostat.]
[N02BE01, acetaminophen, Carboplatin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Carboplatin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Carboplatin.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Carboplatin.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Carboplatin.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB37, idarucizumab, Carboplatin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Mepolizumab.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Carboplatin.]
[L01XG03, ixazomib, Carboplatin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Carboplatin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Alminoprofen.]
[N03AX23, brivaracetam, Carboplatin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ixekizumab.]
[N05BA08, bromazepam, Carboplatin may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Carboplatin may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Carboplatin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Bupivacaine.]
[N05BE01, buspirone, Carboplatin may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Carboplatin is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Arsenic trioxide.]
[M02AA03, clofezone, Carboplatin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Brodalumab.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Balsalazide.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Carboplatin.]
[A06AH05, naldemedine, Carboplatin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Carboplatin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Carboplatin may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Carboplatin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Carboplatin.]
[J05AF06, abacavir, Carboplatin may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Carboplatin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Carboplatin.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Sarilumab.]
[J01MA23, delafloxacin, Carboplatin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Carboplatin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Carboplatin is combined with Vorinostat.]
[C07AB07, bisoprolol, Carboplatin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefprozil.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Carboplatin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Carboplatin.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Carboplatin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Carboplatin.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Bumadizone.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Carboplatin may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, Carboplatin may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Carboplatin.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carboplatin.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Baricitinib.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Carboplatin.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftibuten.]
[J01GB14, plazomicin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Plazomicin is combined with Carboplatin.]
[A16AX14, migalastat, Carboplatin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Carboplatin may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, Carboplatin may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Carboplatin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Inotersen.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Carboplatin.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ravulizumab.]
[A06AX05, prucalopride, Carboplatin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Carboplatin.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Carboplatin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Carboplatin is combined with Siponimod.]
[N06BA14, solriamfetol, Carboplatin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Carboplatin may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Carboplatin is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Carboplatin.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Carboplatin is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Risankizumab.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Carboplatin.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Carboplatin.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Carboplatin.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Carboplatin.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Carboplatin.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefuroxime.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Upadacitinib.]
[N07XX11, pitolisant, Carboplatin may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Carboplatin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Carboplatin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Carboplatin is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Carboplatin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Carboplatin is combined with Diroximel fumarate.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Givosiran.]
[M09AX08, golodirsen, Carboplatin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Carboplatin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Teprotumumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ozanimod.]
[R02AA03, dichlorobenzyl alcohol, Carboplatin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Carboplatin may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Carboplatin.]
[L01XF03, bexarotene, The serum concentration of Bexarotene can be increased when it is combined with Carboplatin.]
[C08CA16, clevidipine, Carboplatin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Carboplatin.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Carboplatin.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluprednidene.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Droxicam.]
[V08CA05, mangafodipir, Carboplatin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Dexketoprofen.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Carboplatin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Stepronin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Satralizumab.]
[P01BA01, chloroquine, Carboplatin may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, Carboplatin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, Carboplatin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Carboplatin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ethenzamide.]
[N02BA03, choline salicylate, Carboplatin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Carboplatin.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Etofenamate.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Carboplatin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Voclosporin.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Fenbufen.]
[C01CA19, fenoldopam, Carboplatin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Carboplatin may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Carboplatin.]
[N02BG07, flupirtine, Carboplatin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carboplatin.]
[A02BA01, cimetidine, Carboplatin may decrease the excretion rate of Cimetidine which could result in a higher serum level.]
[V08CA04, gadoteridol, Carboplatin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Carboplatin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Carboplatin.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pegcetacoplan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Carboplatin is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Anifrolumab.]
[V09AB03, ioflupane I-123, Carboplatin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Carboplatin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Carboplatin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Carboplatin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Levobupivacaine.]
[N06AA04, clomipramine, Carboplatin may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, Carboplatin may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Carboplatin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Deucravacitinib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Carboplatin is combined with Clozapine.]
[J01GB12, arbekacin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Arbekacin is combined with Carboplatin.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Proquazone.]
[M04AC01, colchicine, Carboplatin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Colistin is combined with Carboplatin.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefpirome.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Leflunomide.]
[A04AA03, tropisetron, Carboplatin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Carboplatin may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Imidazole salicylate.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Indobufen.]
[J05AB14, valganciclovir, Carboplatin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Carboplatin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Carboplatin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Carboplatin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Carboplatin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Carboplatin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Carboplatin.]
[N02CC05, almotriptan, Carboplatin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Parecoxib.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Carboplatin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Carboplatin.]
[N05BA10, ketazolam, Carboplatin may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Carboplatin.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboplatin.]
[N03AX09, lamotrigine, Carboplatin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.]
[N07BC04, lofexidine, Carboplatin may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Carboplatin.]
[C09AA03, lisinopril, Carboplatin may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Carboplatin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Meprednisone.]
[J01DH02, meropenem, Carboplatin may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Carboplatin may decrease the excretion rate of Melperone which could result in a higher serum level.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Carboplatin.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Carboplatin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carboplatin.]
[S01XA18, cyclosporine, Carboplatin may increase the immunosuppressive activities of Cyclosporine.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Morniflumate.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Carboplatin.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Carboplatin.]
[N07BB05, nalmefene, Carboplatin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Carboplatin may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Carboplatin may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Carboplatin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Carboplatin may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Carboplatin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Olsalazine.]
[N06AA01, desipramine, Carboplatin may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Carboplatin may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Carboplatin.]
[V04CH02, indigo carmine, Carboplatin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Carboplatin may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Carboplatin.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Carboplatin.]
[N06BA02, dextroamphetamine, Carboplatin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Carboplatin.]
[P03AC04, permethrin, Carboplatin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Carboplatin may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Cinchocaine.]
[R05DA08, pholcodine, Carboplatin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Carboplatin.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Foscarnet.]
[A03AA07, dicyclomine, Carboplatin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Carboplatin may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ixabepilone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pirarubicin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, Carboplatin may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Difluocortolone.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Carboplatin.]
[C01AA05, digoxin, Carboplatin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carboplatin.]
[N02AA03, hydromorphone, Carboplatin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Carboplatin.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Atazanavir.]
[H03BC01, potassium perchlorate, Carboplatin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Carboplatin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Pramocaine.]
[V03AB09, dimercaprol, Carboplatin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Carboplatin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Proglumetacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Carboplatin.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carboplatin.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Carboplatin.]
[S01AX06, resorcinol, Carboplatin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Carboplatin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.]
[R06AE09, levocetirizine, Carboplatin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Carboplatin.]
[G04BE08, tadalafil, Carboplatin may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Carboplatin.]
[C01EB18, ranolazine, Carboplatin may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Salsalate.]
[H05BA01, salmon calcitonin, Carboplatin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Carboplatin may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Carboplatin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Carboplatin may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Doxorubicin.]
[J01AA02, doxycycline, Carboplatin may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[A08AA10, sibutramine, Carboplatin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A12CA02, sodium sulfate, Carboplatin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Carboplatin may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Carboplatin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Carboplatin may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Carboplatin.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Carboplatin.]
[M01AG02, tolfenamic acid, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Carboplatin may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Carboplatin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, Carboplatin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Carboplatin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Carboplatin.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Carboplatin is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Carboplatin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Carboplatin.]
[N06AX16, venlafaxine, Carboplatin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Carboplatin.]
[M01AB04, zomepirac, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Carboplatin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Antilymphocyte immunoglobulin (horse).]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Carboplatin.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Carboplatin.]
[C01DA05, pentaerythritol tetranitrate, Carboplatin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C02AC02, guanfacine, Carboplatin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Carboplatin.]
[L03AX05, pidotimod, Carboplatin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Carboplatin may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Carboplatin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, Carboplatin may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), Carboplatin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Carboplatin may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluticasone.]
[V08CA03, gadodiamide, Carboplatin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01BD05, ibutilide, Carboplatin may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Etidocaine.]
[N01AX07, etomidate, Carboplatin may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Carboplatin.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Carboplatin.]
[P01AX07, trimetrexate, Carboplatin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Carboplatin may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Carboplatin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, Carboplatin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Carboplatin.]
[M01CB01, gold sodium thiomalate, Carboplatin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Carboplatin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin.]
[A16AA01, levocarnitine, Carboplatin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Carboplatin.]
[N02AB03, fentanyl, Carboplatin may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Carboplatin may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Carboplatin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Carboplatin.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Carboplatin.]
[N07AX03, cevimeline, Carboplatin may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Carboplatin may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Floctafenine.]
[J02AC01, fluconazole, Carboplatin may decrease the excretion rate of Fluconazole which could result in a higher serum level.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Carboplatin.]
[V03AB25, flumazenil, Carboplatin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Carboplatin.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Carboplatin.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carboplatin.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carboplatin.]
[N05CD01, flurazepam, Carboplatin may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Carboplatin.]
[L02BB01, flutamide, Carboplatin may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Carboplatin may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Carboplatin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Framycetin is combined with Carboplatin.]
[L01BC03, tegafur, Carboplatin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Furosemide is combined with Carboplatin.]
[N05CF04, eszopiclone, Carboplatin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[S01AD09, ganciclovir, Carboplatin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[C10AB04, gemfibrozil, Carboplatin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Carboplatin may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Dasatinib.]
[A10BB07, glipizide, Carboplatin may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Carboplatin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[L01EX02, sorafenib, The risk or severity of death can be increased when Sorafenib is combined with Carboplatin.]
[M01CB04, aurothioglucose, Carboplatin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Carboplatin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Carboplatin.]
[C09AA09, fosinopril, Carboplatin may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Carboplatin may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Carboplatin may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Carboplatin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AH04, quetiapine, Carboplatin may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Carboplatin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Carboplatin.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Carboplatin.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Carboplatin.]
[G03DC01, allylestrenol, Carboplatin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Carboplatin.]
[C01CE02, milrinone, Carboplatin may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Carboplatin.]
[M02AA26, nimesulide, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Nimesulide.]
[C09AA04, perindopril, Carboplatin may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Carboplatin may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Carboplatin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Carboplatin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Carboplatin may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Carboplatin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Carboplatin is combined with Hydroxyurea.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ibuprofen.]
[B05XA08, sodium acetate, Carboplatin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Carboplatin.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ifosfamide.]
[N06AA02, imipramine, Carboplatin may decrease the excretion rate of Imipramine which could result in a higher serum level.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Carboplatin is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Carboplatin is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Carboplatin is combined with Topotecan.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Carboplatin.]
[A11HA07, inositol, Carboplatin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carboplatin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carboplatin.]
[N06AX17, milnacipran, Carboplatin may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Carboplatin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Articaine.]
[A10BH01, sitagliptin, Carboplatin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Carboplatin may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Carboplatin may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Carboplatin.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin.]
[V03AB01, ipecac, Carboplatin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[J04AC01, isoniazid, Carboplatin may decrease the excretion rate of Isoniazid which could result in a higher serum level.]
[J05AX05, inosine pranobex, Carboplatin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[D10BA01, isotretinoin, Carboplatin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Carboplatin.]
[S01AA24, kanamycin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Kanamycin is combined with Carboplatin.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Tocilizumab.]
[N01AX03, ketamine, Carboplatin may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Carboplatin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Carboplatin.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Ketoprofen.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Carboplatin is combined with Abatacept.]
[C07AG01, labetalol, Carboplatin may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, Carboplatin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Carboplatin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Carboplatin.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Carboplatin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Lidocaine.]
[S01AA21, amikacin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Amikacin is combined with Carboplatin.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Lomustine.]
[N05BA06, lorazepam, Carboplatin may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Carboplatin is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Carboplatin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Carboplatin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Carboplatin.]
[N06AA21, maprotiline, Carboplatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Carboplatin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Carboplatin.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Carboplatin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Carboplatin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Carboplatin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Carboplatin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Carboplatin is combined with Melphalan.]
[N06DX01, memantine, Carboplatin may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Carboplatin may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Mepivacaine.]
[G04BX16, tiopronin, Carboplatin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Carboplatin may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, Carboplatin may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Carboplatin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Carboplatin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Carboplatin may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Carboplatin.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Carboplatin.]
[A11HA02, pyridoxine, Carboplatin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Carboplatin.]
[D05BA02, methoxsalen, Carboplatin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Carboplatin may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Carboplatin may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Methylprednisolone.]
[G03EK01, methyltestosterone, Carboplatin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, Carboplatin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Carboplatin may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[V04CD01, metyrapone, Carboplatin may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Carboplatin.]
[N05CD08, midazolam, Carboplatin may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Carboplatin.]
[J05AH01, zanamivir, Carboplatin may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carboplatin.]
[N06AA09, amitriptyline, Carboplatin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[A04AA05, palonosetron, Carboplatin may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Latamoxef.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Carboplatin is combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Carboplatin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Carboplatin is combined with Mycophenolic acid.]
[N03AB05, fosphenytoin, Carboplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin.]
[C07AA12, nadolol, Carboplatin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Carboplatin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Carboplatin may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Carboplatin.]
[N06BA01, amphetamine, Carboplatin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Carboplatin.]
[N06AX21, duloxetine, Carboplatin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Carboplatin may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carboplatin.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Carboplatin is combined with Docetaxel.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Neomycin.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Carboplatin.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Carboplatin.]
[S01AA19, ampicillin, Carboplatin may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Carboplatin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Netilmicin is combined with Carboplatin.]
[N06AX23, desvenlafaxine, Carboplatin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Carboplatin.]
[C01CE01, inamrinone, Carboplatin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Carboplatin.]
[C08CA05, nifedipine, Carboplatin may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Niflumic acid.]
[C08CA07, nisoldipine, Carboplatin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Carboplatin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Carboplatin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Carboplatin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Carboplatin may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Carboplatin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Carboplatin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Carboplatin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Carboplatin is combined with Rilonacept.]
[N02AA02, opium, Carboplatin may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Carboplatin.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Carboplatin.]
[G04CA02, tamsulosin, Carboplatin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Zoledronic acid.]
[J01CF04, oxacillin, Carboplatin may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Carboplatin may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Oxyphenbutazone.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Carboplatin.]
[J04AB30, capreomycin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Capreomycin is combined with Carboplatin.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Carboplatin is combined with Paramethasone.]
[A07AA06, paromomycin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Paromomycin is combined with Carboplatin.]
[G04BD11, fesoterodine, Carboplatin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Carboplatin may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Carboplatin.]
[J01CE09, penicillin G procaine, Carboplatin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carboplatin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carboplatin.]
[N05CA01, pentobarbital, Carboplatin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Carboplatin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Carboplatin.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Carboplatin.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Phenazopyridine.]
[N06AF03, phenelzine, Carboplatin may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Carboplatin.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Carboplatin.]
[V03AB36, phentolamine, Carboplatin may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Carboplatin.]
[N03AB02, phenytoin, Carboplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Golimumab.]
[S01AE05, levofloxacin, Carboplatin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Carboplatin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Carboplatin.]
[C07AA03, pindolol, Carboplatin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01CA12, piperacillin, Carboplatin may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[N06BX03, piracetam, Carboplatin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Carboplatin.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefditoren.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Carboplatin.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Carboplatin.]
[A10BG02, rosiglitazone, Carboplatin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Carboplatin is combined with Polymyxin B.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH03, saxagliptin, Carboplatin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Carboplatin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Carboplatin.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Carboplatin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Prilocaine.]
[M04AB01, probenecid, Carboplatin may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Carboplatin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Carboplatin is combined with Procarbazine.]
[C10AB05, fenofibrate, Carboplatin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[R06AD02, promethazine, Carboplatin may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Carboplatin may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[C07AA05, propranolol, Carboplatin may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carboplatin.]
[N02CC04, rizatriptan, Carboplatin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Carboplatin.]
[N07XX07, dalfampridine, Carboplatin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Carboplatin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Carboplatin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Carboplatin.]
[C01BA01, quinidine, Carboplatin may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, Carboplatin may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA02, reserpine, Carboplatin may decrease the excretion rate of Reserpine which could result in a higher serum level.]
[J05AP01, ribavirin, Carboplatin may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carboplatin.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Carboplatin.]
[N05CA06, secobarbital, Carboplatin may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Carboplatin is combined with Obinutuzumab.]
[J01GB08, sisomicin, The risk or severity of ototoxicity and nephrotoxicity can be increased when Sisomicin is combined with Carboplatin.]
[A12CD01, sodium fluoride, Carboplatin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Carboplatin.]
[V04CC01, sorbitol, Carboplatin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Carboplatin is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carboplatin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Carboplatin is combined with Hydrocortisone butyrate.]
[C01DA14, isosorbide mononitrate, Carboplatin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Carboplatin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Tiaprofenic acid.]
